Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Neuropharmacology. 2018 Sep 17;145(Pt B):268–282. doi: 10.1016/j.neuropharm.2018.09.024
TBI Model Species Treatment Paradigm Outcomes Reference
FPI Rat Twice daily 10 mg/kg P7C3–A20 IP 30 min post TBI for 7 days Decreased contusion volume; protected pericontusional mature neurons; augmented adult hippocampal neurogenesis; improved neurobehavioral outcomes Blaya et al., 2014
FPI Rat Twice daily 10 mg/kg P7C3–A20 IP 30 min or 3 hr post TBI for 7 days Preserved injury-induced reduction in LTP Unpublished
CCI Mouse Twice daily 10 mg/kg P7C3–A20 IP 30 min post TBI for 7 days Increased early-stage adult hippocampal neurogenesis Unpublished
Blast Mouse 3, 10, and 30 mg/kg/day P7C3–S243 IP or oral 24 hrs post TBI for 11 days Blocked axonal degeneration in brain; improved learning, memory, motor coordination; preserved synaptic plasticity Yin et al, 2014
FPI Rat Twice daily 10 mg/kg P7C3–A20 IP 30 min post TBI for 7 days Reduced reactive phenotype of activated microglia, macrophages, astrocytes (qualitative) Unpublished
HHS Vulnerability Disclosure